Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of “Buy” by Analysts

Arvinas, Inc. (NASDAQ:ARVN) has received a consensus recommendation of “Buy” from the twelve research firms that are currently covering the company, MarketBeat Ratings reports. Twelve equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $60.00.

Several research firms have commented on ARVN. BMO Capital Markets reissued an “outperform” rating and set a $82.00 price target (down from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th. Wedbush reissued an “outperform” rating and set a $57.00 price target on shares of Arvinas in a research note on Tuesday, February 11th. Oppenheimer lifted their price target on shares of Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Finally, Guggenheim reissued a “buy” rating and set a $57.00 price target on shares of Arvinas in a research note on Wednesday, February 12th.

Arvinas Price Performance

Shares of ARVN opened at $17.77 on Friday. The firm’s 50 day simple moving average is $18.49 and its 200 day simple moving average is $22.94. The company has a market capitalization of $1.22 billion, a P/E ratio of -6.42 and a beta of 1.88. Arvinas has a 1-year low of $16.61 and a 1-year high of $51.51.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the previous year, the company earned ($2.53) EPS. On average, equities analysts anticipate that Arvinas will post -3.81 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in Arvinas during the 4th quarter valued at $28,000. nVerses Capital LLC purchased a new position in Arvinas during the 3rd quarter valued at $39,000. KBC Group NV increased its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after purchasing an additional 440 shares during the period. Finally, Quantbot Technologies LP increased its position in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares during the period. 95.19% of the stock is owned by hedge funds and other institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.